| 亞洲大學 |
2017-12 |
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
|
Hs, Hsi-Hsien;Hsu, Hsi-Hsien;Ming-Cheng, Cheng C;Chen, Ming-Cheng;Rathinasamy;Baskaran, Rathinasamy;Lin, Yueh-Min;Cecilia, H. D;Day, Cecilia H.;Lin, Yi-Jiun;Chuan-Chou, T;Tu, Chuan-Chou;Viswanadha, Viswanadha V;Padma, Viswanadha Vijaya;Kuo, Wei-Wen;黃志揚;Huang, Chih-yang |
| 臺大學術典藏 |
2020-03-05T06:28:40Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Cheng A.-L.; Chang Y.-L.; Yeh K.-H.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liang J.-T.; Lin Y.-.; Liang Y.-H.; Tsai J.-H.; JAU-YU LIAU |
| 臺大學術典藏 |
2020-02-25T05:15:26Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Liau J.-Y.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-.; Liang Y.-H.; Tsai J.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:15Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:25Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liau J.-Y.; Liang J.-T.; Tsai J.-H.; Liang Y.-H.; Lin Y.-.; Lin Y.-.;Liang Y.-H.;Tsai J.-H.;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Yih-Leong Chang;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T07:31:48Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.;Liang Y.-H.;Jia-Huei Tsai;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Chang Y.-L.;Yeh K.-H.;Cheng A.-L.; Lin Y.-.; Liang Y.-H.; JIA-HUEI TSAI; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-03T02:20:57Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:42:23Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.;Liang Y.-H.;Tsai J.-H.;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Chang Y.-L.;Kun-Huei Yeh;Cheng A.-L.; Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-10T07:58:43Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; LI-HUI TSENG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
